Related Experiment Video
Updated: Jul 18, 2026

07:22
Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
Published on: March 28, 2013
PPAR delta agonists and metabolic diseases
Current Atherosclerosis Reports
|December 16, 2006
Summary
Peroxisome proliferator-activated receptors (PPARs), particularly PPARdelta, regulate lipid metabolism and energy. PPARdelta agonists show promise for treating metabolic diseases like atherosclerosis and insulin resistance.
Area of Science:
- Biochemistry
- Metabolic Research
- Molecular Biology
Background:
- Peroxisome proliferator-activated receptors (PPARs) are crucial transcription factors governing lipid metabolism and energy balance.
- PPARalpha and PPARgamma are established therapeutic targets for hypertriglyceridemia and type 2 diabetes.
- The physiological role of PPARdelta has been less understood due to its widespread tissue expression.
Purpose of the Study:
- To elucidate the diverse physiological functions of PPARdelta.
- To explore the therapeutic potential of PPARdelta agonists in metabolic diseases.
Main Methods:
- Development of transgenic mouse models.
- Identification and utilization of high-affinity synthetic PPARdelta ligands.
Main Results:
- Revealed diverse activities of PPARdelta in key metabolic tissues: skeletal muscle, adipose tissue, liver, and macrophages.
- Demonstrated the involvement of PPARdelta in regulating lipid metabolism and energy homeostasis.
- Highlighted the broad physiological relevance of PPARdelta.
Conclusions:
- PPARdelta plays a significant role in metabolic regulation across multiple tissues.
- PPARdelta agonists represent a promising therapeutic strategy for metabolic disorders such as atherosclerosis and insulin resistance.
Related Concept Videos
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
G Protein-coupled Receptors
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...